Search
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalIt is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912] … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.
Felodipine
go.drugbank.com/drugs/DB01023ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity.
Categories: Antihypertensive Agents Indicated for HypertensionProducts: FELODIPIN 2.5MG RET HEU NTerbutaline
go.drugbank.com/drugs/DB00871ApprovedInvestigational[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088] … Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.
Mixtures: BRICANYL EXCategories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesZopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081] … [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … 2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose.
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedHydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. … Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16588ApprovedUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Mixtures: FLUARIX TETRA SUSPENSION FOR INJECTIONDoxacurium
go.drugbank.com/drugs/DB01135ApprovedWithdrawnDoxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigationalRelebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam]. … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use